Ascension Providence will treat qualifying COVID-19 patients with bamlanivimab following its emergency use authorization by the FDA.
The drug has been approved for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients who are at high risk of progressing to severe COVID-19 or hospitalization.
Patients must be 12-years-old or older and weigh at least 40 kilograms (88.18 pounds). Additional criteria for consideration include if the patient is not hospitalized, has one or more COVID-19 symptom and is within 10 days of symptom onset with a COVID-positive test within the last three days.
Ascension Providence has received an allotment of the therapy and is working to set up an outpatient infusion clinic site. The group plans to begin providing the treatment as early as next week.
The therapy is administered through an IV and can be given at physician-order only.
